Special Issue

Drug-Induced Hepatotoxicity: From Pathology to Novel Therapeutic Approaches

Message from the Guest Editor

The liver is the main organ for metabolized and detoxification chemicals and is susceptible to the toxicity of these agents. Drugs associated with Drug-induced liver injury (DILI) may cause injury in a dose-dependent, predictable hepatotoxicity or in an unpredictable hepatotoxicity in susceptible individuals. Drugs or their toxic metabolites cause the activation of MAP kinases or deactivation of signaling pathways. Then, it causes the impairment of mitochondrial function, oxidative stress, mitochondria damaged, and hepatocyte death. Moreover, the endogenous defense system of the liver is made up of endogenous nonprotein antioxidants and endogenous protein antioxidants. The main endogenous antioxidants are glutathione, lipoic acid, bilirubin, ferritin, superoxide dismutase, catalase, and glutathione peroxidase. Their main function is to maintain redox homeostasis in the liver. The aim of this Special Issue on Drug-Induced Hepatotoxicity is to discuss updated recent findings in mechanisms of drug induced hepatoxicity and potential therapeutic targets. Original articles and review articles on the following topics are welcome.

Guest Editor

Dr. Sanda Win

Division of Gastrointestinal and Liver Disease, Department of Medicine, Keck School of Medicine, University of Southern California, 2011 Zonal Avenue, HMR 612, Los Angeles, CA 90089, USA

Deadline for manuscript submissions

closed (31 July 2022)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/84422

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).